Developing Alzheimer's diagnostic, treatment
This article was originally published in Start Up
Theories regarding the basis of Alzheimer’s disease have focused primarily on beta-amyloid and tau proteins, but still today no one can say for certain whether these proteins are causative, or merely symptomatic of some other disease process. Neurotrope Inc. is pursuing a new suspect, protein kinase C-epsilon, based on observations that a shortage of PKCe in the brain correlates with erosion of synapses that prevents neurons from functioning properly, and thus leads to loss of neural and motor skills.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.